Compare Enveric Biosciences Inc (ENVB) vs Keysight Technologies Inc (KEYS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Enveric Biosciences Inc vs Keysight Technologies Inc — how do they compare? Enveric Biosciences Inc trades at $1.45 (market cap $6.80M), while Keysight Technologies Inc trades at $376.88 (market cap $63.79B). The key difference: Keysight Technologies Inc is far larger — about 9380.9× Enveric Biosciences Inc's market cap, and Keysight Technologies Inc is trading nearer its 52-week high, Enveric Biosciences Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Enveric Biosciences Inc for 14 Days and Keysight Technologies Inc for 56 Days on average.
| ENVB | KEYS | |
|---|---|---|
Market Cap | $6.80M | $63.79B |
Volume | 64,867 | 1,435,384 |
Sector | Health | Technology |
52-Week High | $10.80 | $387.90 |
52-Week Low | $1.27 | $159.49 |
Typical Hold Time | 14 Days | 56 Days |
Enterprise Value | -$1.49M | $63.93B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ENVB trades at $1.45, down 3.01% on the day, with a bearish technical signal driven by moving averages. The company reported no revenue in 2025 and a net loss of $8.77 million, though it has consistently beaten quarterly EPS expectations. Recent positive developments include a new U.S. patent allowance for its non-hallucinogenic mescaline derivatives and participation in investor conferences.
The outlook is mixed; analyst consensus is 75% buy with strong earnings beats, but high negative ROE/ROA and operational cash burn pose significant risks. Investment opportunity hinges on successful drug development, while key risks include funding needs and clinical trial outcomes.
KEYS trades at $381.49, down 1.65% on the day, with a bullish technical signal from moving averages and strong fundamental performance including three consecutive quarterly earnings beats. Revenue for 2025 reached $5.38 billion with a net income margin of 19.14%, while analyst consensus is strongly bullish with an 81.25% buy rating and a $416.63 price target. Recent news highlights growth in AI infrastructure and 6G technology development.
The outlook for KEYS is positive, driven by accelerating earnings and expanding AI and 6G opportunities, though high valuation multiples and supply chain constraints present risks. Upside potential exists if the company continues to exceed earnings expectations and capitalize on tech sector demand.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Enveric Biosciences Inc
Enveric Biosciences is a biotechnology company focused on developing next-generation psychedelic-inspired therapies for mental health and neuropsychiatric disorders.
Read more on ENVB →About Keysight Technologies Inc
Keysight Technologies is a leader in the field of testing and measurement, helping electronics OEMs and suppliers alike bring products to market to fit industry standards and specifications. Keysight specializes in the communications market, but also supplies into the government, automotive, industrial, and semiconductor manufacturing markets. Keysight's solutions include testing tools, analytical software, and services. The firm's stated objective is to reduce time to market and improve efficiency at its more than 30,000 customers.
Read more on KEYS →
